阿托伐他汀对造影剂肾病的预防  

Effect of Atorvastatin on Preventing Contrast-Induced Nephropathy

作　　者：石增刚[1] 桑更生[1] 张亮[1] 何佰生[1] 

机构地区：[1]安徽省蚌埠市第三人民医院心内科,安徽蚌埠233000

出　　处：《内蒙古医学杂志》2013年第6期690-691,共2页Inner Mongolia Medical Journal

摘　　要：目的:观察阿托伐他汀对行冠脉介入治疗(PCI)患者造影剂肾病(CIN)的预防作用。方法:200例行PCI患者随机分为他汀组(110例)及对照组(90例),他汀组术前3 d开始每晚服阿托伐他汀40mg。比较两组之间术前及术后48 h血肌酐(Scr)的变化。结果:对照组术后Scr显著高于他汀组(P<0.05);造影剂肾病在对照组的发病率显著高于他汀组(P<0.05)。结论:PCI术前使用他汀类药物对CIN有一定的预防作用。Objective：To investigate the efficacy of atorvastatin in preventing contrast- induced nephropa- thy （CIN）. Methods：Two hundred patients undergoing percutaneous coronary intervention （PCI） were random- ly divided into atorvastatin group （n = 110） and control group （n = 90）. Patients in atorvastatin group were giv- en atorvastatin （40mg qn）72 hours before PCI. Serum creatine （Scr） levels before and 48 hours after procedure were compared between the two groups. Results： The levels of Scr in control group was significantly increased comparing with the atorvastatin group after PCI （P 〈： 0.05） ; the CIN incidence in control group was significant- ly higher than in atorvastatin group. Conelusion：Statins maybe have some effect on preventing CIN; treatment with statins before PCI probably reduce the incidence of CIN.

关 键 词：他汀类药物 造影剂肾病 经皮冠状动脉介入 预防 

分 类 号：R586[医药卫生—内分泌] R543.31[医药卫生—内科学]